Purchase Order 75N91025P00119
Award Date
12/28/24
Potential Completion Date
12/27/25
Potential Value
$15K
Federal Agency
National Cancer Institute
Awardee
Leinco Technologies, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order (HT942525F0013) awarded to Leinco Technologies, Inc., a self-certified small disadvantaged business and manufacturer of goods, by the Defense Health Agency (DHA) on October 31, 2024. The $33,125.00 firm fixed-price contract is for the provision of monoclonal antibodies derived from in-vivo genetically immunized knockout mice expressing the interferon-alpha/beta receptor alpha chain protein. This contract supports the agency's research and development efforts related to...
The U.S. Defense Health Agency awarded a $34,225 firm-fixed-price delivery order contract to Leinco Technologies, Inc., a self-certified small disadvantaged business and manufacturer of goods. The contract is for the provision of monoclonal antibodies from knockout mice that have been in-vivo genetically immunized with interferon-alpha/beta receptor alpha chain protein. This contract award supports federal research initiatives related to COVID-19 and other viral pathogens. Leinco Technologies...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $22,388,857.00 contract is for the Proteomic Characterization Laboratory and supports the President's Department of Government Efficiency Cost Efficiency Initiative. The contract does not have a set-aside designation, indicating Leidos Biomedical...
This is a $4,082,230.25 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for infrastructure improvements and supports the President's Department of Government Efficiency Cost Efficiency Initiative. The contract does not have a set-aside designation, indicating Leidos Biomedical Research Inc.'s competitive capabilities in providing comprehensive biomedical research...
This is a federal contract award issued by the National Cancer Institute (NCI), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract, identified as 75N91019D00024|75N91022F00004, is for the GS-524 PHASE 1 TRIAL, with a ceiling value of $12,045,876.00. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, and has an ultimate completion date of July 6, 2026. This award is not associated with a set-aside designation. Leidos...
This is a $4,490,899.23 cost-no-fee Delivery Order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is to develop and implement capacity to monitor circulating tumor nucleic acid, with a period of performance ending on September 25, 2020. This contract is not associated with a set-aside program. Leidos Biomedical Research Inc. operates as a...
This is a $10,719,410.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for proteomic and antibody production and characterization services. The award is associated with an existing Indefinite Delivery Contract between NCI and Leidos Biomedical Research Inc., with a potential value of $6.6 billion. Leidos Biomedical Research Inc. serves as a Federally Funded...
This is a Cost Plus Fixed Fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for Good Manufacturing Practice (GMP) manufacturing of the LMB-2 immunotoxin, with a ceiling value of $1,021,037.00 and a performance period ending on September 24, 2025. The contract is not set aside for any specific socioeconomic category. Leidos Biomedical Research Inc. is an established Federally...
This federal contract award is for the "VRC RAPID MANUFACTURING RESPONSE: NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT" awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency. The $21,593,558.00 cost-plus-fixed-fee contract has an ultimate completion date of July 2, 2028 and was awarded on September 16, 2022 to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. Leidos Biomedical Research Inc. serves...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., to facilitate the conduct of an observational study to characterize patients with COVID-19 infection (10,000 subjects). The contract has a ceiling value of $18,109,529.00 with a period of performance through January 31, 2027. It is a cost-plus-fixed-fee delivery order contract with no set-aside...